2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5674 Efficacy of frontline combination targeted therapy in chronic lymphocytic leukemia with highly complex karyotype: A retrospective analysis

Kiyomi Mashima, MD, PhD, Svitlana Tyekucheva, PhD2, Fernanda Santos Azevedo, MD3, Stacey M. Fernandes, BS4, Roberta Azevedo, MD5, Sungchul Choi, MD6, Ava Bidgoli7, Paulina Predko, BS8, Mariia Mikhaleva, MD9, Stephen Martindale, BA10, Uday Aditya Sarkar, PhD11, Saurabh Yadav, PhD12, Binu Kandathilparambil Sasi, PhD13, Aishath Naeem, PhD14, Inhye E Ahn, MD15, Matthew S Davids, MD, MMSc16, Jennifer R. Brown, MD, PhD17
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Background: Complex karyotype (CK) has emerged as an independent prognostic factor for CLL outcome in recent years. Highly complex karyotype (CK with >=5 abnormalities: CK5) has been reported as conferring a particularly poor prognosis even with targeted therapies, and the optimal frontline therapy remains controversial. We aimed to evaluate the efficacy of frontline targeted therapies focusing on patients with CK5, given the limited prognostic value of intermediate CK (>=3), who were treated at Dana-Farber Cancer Institute.

Methods: We retrospectively analyzed 731 CLL patients from the DFCI database initiating frontline targeted therapy. To minimize era bias and ensure all therapeutic options were accessible, inclusion was restricted to patients initiating therapy from 2018 onward, concurrent with the availability of targeted regimens. Following these exclusions, a final cohort of 583 with documented clinical responses and essential baseline prognostic markers, including IGHV mutational status, were evaluated. These patients were stratified into three arms: BTK inhibitor +/- anti-CD20 mAb (BTKi-based), BCL2 inhibitor +/- anti-CD20 mAb (BCL2i-based), and combination (BTKi+BCL2i+/-CD20 mAb) therapy. Patients receiving PI3K inhibitor combinations were excluded. Median follow-up time for included cases was 2.70 years (95% CI 2.44-3.05). TTNT/D (Time to Next Treatment or Death) was evaluated using multivariable Cox proportional hazards models to adjust for confounding factors and assess interactions. 24-month estimates of TTNT/D were calculated using the Kaplan-Meier method.

Results: Among 583 cases (median age 67 years), 306 received BTKi-based, 157 BCL2i-based, and 120 combination therapy. 87 patients (14.9 %) harbored CK5. Among the 87 patients with CK5, 55 (63%) had concurrent TP53 aberration, compared to 86 (17%) of the 496 patients without CK5. Reflecting the selection of therapy, patients receiving BCL2i-based therapy predominantly lacked high-risk baseline features. In contrast, baseline profiles including IGHV and TP53 aberration were comparable between the BTKi-based cohort and combination cohorts, with the exception of age, which was younger in the combination group (median 65 vs 69 years; p = 0.002). Given the general avoidance of BCL2i-based therapy in high-risk patients, comparative efficacy analyses were restricted to BTKi-based therapy versus combo.

In a multivariable Cox model adjusted for treatment, IGHV mutation status, TP53 aberration, and CK5, unmutated IGHV (HR 1.69, 95% CI 1.09-2.61, p = 0.018) and CK5 (HR 1.92, 95% CI 1.27-2.91, p = 0.002) were identified as independent adverse prognostic factors for TTNT/D. TP53 aberration lost independent significance in this adjusted model (HR 1.07, 95% CI 0.73-1.58, p=0.7).  In addition, in interaction analysis, no significant interaction was observed between frontline treatment and CK5 (p=0.72), indicating that CK5 consistently shortens TTNT/D across both therapies including combo. Nevertheless, despite a longer median follow-up (3.81 vs 2.72 years), combination therapy significantly improved TTNT/D compared to BTKi-based therapy within both the CK5-negative (HR 0.36, 95% CI 0.21-0.62, p<0.001; 24-month TTNT/D: 93.7% vs 79.2%) and CK5-positive (HR 0.36, 95% CI 0.16-0.82, p=0.015; 24-month TTNT/D: 90.0% vs 64.7%) subgroups. The treatment HR estimated in the entire cohort, regardless of CK5 status, was 0.36, 95% CI 0.22-0.56, p<0.001; with 24-month TTNT/D: 92.8% for combo vs 76.3% for BTKi-based therapy. This trend was maintained even after adjusting for the age difference between the BTKi-based therapy and combination arms.

Conclusions: Our retrospective data confirm CK5 as an independent adverse prognostic factor for frontline CLL in the targeted therapy era, while TP53 aberration lost independent significance. Notably, frontline combination regimens significantly improved TTNT/D compared to BTKi-based therapy across both CK5-positive and CK5-negative subgroups without treatment interaction. These findings highlight combination therapy as a highly effective approach for high-risk CK5 CLL, warranting prospective validation.
Kiyomi Mashima, MD, PhD: No relevant conflicts of interest to declare.